Browsing by Author "Rabagliati B., Ricardo"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Consenso: Manejo racional del paciente con cáncer, neutropenia y fiebre
    (2005) Santolaya de P., María Elena; Rabagliati B., Ricardo; Bidart H., Teresa; Payá G., Ernesto; Guzmán D., Ana M.; Morales I., Ricardo; Braun J., Stephanie; Bronfman F., Lucía; Ferrés G., Marcela; Flores P., Claudio; García C., Patricia; Letelier Saavedra, Luz María; Puga L., Bárbara; Salgado M., Carmen; Thompson M., Luis; Tordecilla C., Juan; Zubieta A., Marcela
  • Thumbnail Image
    Item
    SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study
    (2022) Dib Marambio, Martín Javier; Le Corre Pérez, Monique Nicole; Ortiz Koh, Catalina Alejandra; García, Daniel; Ferrés, Marcela; Martínez Valdebenito, Constanza; Ruiz-Tagle, Cinthya; Ojeda Valenzuela, María José; Espinoza Sepúlveda, Manuel Antonio; Jara Contreras, Aquiles; Arab Verdugo, Juan Pablo; Rabagliati B., Ricardo; Vizcaya Altamirano, Cecilia; Ceballos, María Elena; Sarmiento Maldonado, Mauricio; Mondaca Contreras, Sebastián Patricio; Viñuela Morales, Macarena Rocío; Pastore Thomson, Antonia; Szwarcfiter Neiman, Vania; Galdames Lavín, Elizabeth Alejandra; Barrera Vásquez, Aldo Vincent; Castro Gálvez, Pablo Federico; Gálvez Arriagada, Nicolás Marcelo Salvador; Soto Ramírez, Jorge Andrés; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes; Nervi Nattero, Bruno; Balcells Marty, María Elvira
    Solid-organ transplant (SOT) recipients have worse COVID-19 outcomes than general population and effective immunisation in these patients is essential but more difficult to reach. We aimed to determine the immunogenicity of an mRNA SARS-CoV-2 vaccine booster in SOT recipients previously immunised with either inactivated or homologous SARS-CoV-2 mRNA vaccine. Methods: Prospective cohort study of SOT recipients under medical care at Red de Salud UC-CHRISTUS, Chile, previously vaccinated with either CoronaVac or BNT162b2. All participants received a BNT162b2 vaccine booster. The primary study end point was anti-SARS-CoV-2 total IgG antibodies (TAb) seropositivity at 8-12 weeks (56-84 days) post booster. Secondary end points included neutralising antibodies (NAb) and specific T-cell responses. Findings: A total of 140 (50% kidney, 38% liver, 6% heart) SOT recipients (mean age 54 [13.6] years; 64 [46%] women) were included. Of them, 62 had homologous (three doses of BNT162b2) and 78 heterologous vaccine schedules (two doses of CoronaVac followed by BNT162b2 booster). Boosters were received at a median of 21.3 weeks after primary vaccination. The proportion achieving TAb seropositivity (82.3% vs 65.4%, P = 0.035) and NAb positivity (77.4% vs 55.1%, P = 0.007) were higher for the homologous versus the heterologous group. On the other hand, the number of IFN-γ and IL-2 secreting SARS-CoV-2-specific T-cells did not differ significantly between groups. Interpretation: This cohort study shows that homologous mRNA vaccine priming plus boosting in SOT recipients, reaches a significantly higher humoral immune response than inactivated SARS-CoV-2 vaccine priming followed by heterologous mRNA booster.
  • Thumbnail Image
    Item
    Tuberculosis en individuos con infección por VIH en Chile: Estudio de prevalencia e impacto sobre mortalidad
    (2008) Villarroel del Pino, Luis A.; Rabagliati B., Ricardo; Balcells Marty, María Elvira; Karzulovic Busch, Lorena Karina; Pérez Cortés, Carlos
    Background: Tuberculosis (TB) in Chile is reaching the elimination phase; however, in HIV positive individuals the incidence ofTB in still very high. Aim To describe the association between TB and HIV in different geographical regions in Chile, and to determine the association between TB and HIV/AIDS mortality. Patients and methods: A retrospective study that included individuals from the main HIV clinics from four regions with different TB prevalence in the general population (per 100,000): Arica (>30), Concepcion/Arauco (25-29), Valparaiso/San Antonio (20-24) and Metropolitana Sur-Oriente (SSMSO) (<20), attended between January 1998 and September 2004. Results: Nine hundred and twelve HIV positive individuals were included. Gobal prevalence ofTB was 6.2% [95% confidence intervals (Cl) 5.2-7.2%]. TB was more common in older subjects (p =0.039) and those with lower CD4 counts (p <0.001) and higher HIV viral load (p =0.033). In 66% of cases, the disease had a pulmonary localization. TB was the recorded cause of death in 7.4% of subjects. Only 29% of patients had a tuberculin skin test performed at the moment of HIV diagnosis. The prevalence of TB in HIV positive patients, followed the trend of TB prevalence in the general population: Concepcion/Arauco (11.9%), Valparaiso/San Antonio (7.1%) and SSMSO (3.9%). However HIV positive subjects from Arica showed an unexpectedly low TB prevalence (5.5%). Conclusions: TB in HIV/AIDS patients included in this study is over 300 times more prevalent than in the general population. TB prevalence in HIV positive subjects follows regional TB prevalence, excepting Arica. Effectiveness and feasibility of latent TB diagnostic strategies and treatment in HIV positive individuals should be reviewed.
  • Thumbnail Image
    Item
    Tuberculosis en individuos con infección por VIH en Chile: Estudio de prevalencia e impacto sobre mortalidad
    (SOC MEDICA SANTIAGO, 2008) Villarroel del Pino, Luis A.; Rabagliati B., Ricardo; Balcells Marty, María Elvira; Karzulovic Busch, Lorena Karina; Pérez Cortés, Carlos
    Background: Tuberculosis (TB) in Chile is reaching the elimination phase, however, in HIV positive individual the incidence of TB in still very high. Aim: To describe the association between TB and HIV in different geographical regions in Chile, and to determine the association between 773 and HIV/AIDS) mortality. Patients and methods: A retrospective study that included individuals from the main HIV clinics from four regions with different TB prevalence in the general population (per 100,000): Arica (> 30), Concepcion/Arauco (25-29), Valparaiso/San Antonio (20-24) and Metropolitana Sur-Oriente (SSMSO) (< 20), attended between january 1998 and september 2004. Results. Nine hundred and twelve HIV positive individuals were included. Gobal prevalence of TB was 6.2% [95916 confidence intervals (Q) 5-2-72%. TB was more common in older subjects (p =0.039) and those with lower CD4 counts (p < 0.001) and higher HIV viral load (p =0.033). In 66% of cased, the disease bad a pulmonary localization. TB was the recorded cause (of death in 7.4% of subjects. Only 2996 of patients bad a tuberculin skin test performed at the moment of HIV diagnosis. The prevalence of 773 in HIV positive patients, followed the trend of TB prevalence in the general population: Concepcion/Arauco (11-9%), Valparaiso/San Antonio (71%) and SSMSO (3.9%). However HIV positive subjects from Arica showed an unexpectedly low 773 prevalence (5.5%). Conclusions: TB in HIV/AIDS patients included in this study is over 300 times more prevalent than in the general population. TB prevalence in HIV positive subjects follows regional TB prevalence, excepting Arica. Effectiveness and feasibility of latent TB diagnostic strategies and treatment in HIV positive individuals should be reviewed (Rev Med Chile 2008; 136: 578-86).